Time trends in high blood pressure control and the use of antihypertensive medications in older adults: The Cardiovascular Health Study

Archives of Internal Medicine

Volumn 162, Issue 20, 2002, Pages 2325-2332

  Psaty, Bruce M ^a   Manolio, Teri A ^c   Smith, Nicholas L ^b   Heckbert, Susan R ^b   Gottdiener, John S ^d   Burke, Gregory L ^e   Weissfeld, Joel ^f   Enright, Paul ^g   Lumley, Thomas ^b   Powe, Neil ^h   Furberg, Curt D ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d ST FRANCIS HOSPITAL   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g NONE

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RACE; UNITED STATES;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; AWARENESS; COHORT STUDIES; DRUG THERAPY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERTENSION; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0037111725     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.20.2325     Document Type: Article

References (61)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:116-122.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment, II: Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143-1152.
3. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mild hypertension: Results of the Hypertension Detection and Follow-up Program. N Engl J Med. 1982;307:976-980.
4. Rutan GH, McDonald RH, Kuller LH. A historical perspective of elevated systolic vs diastolic blood pressure from an epidemiological and clinical trial viewpoint. J Clin Epidemiol 1989;42:663-673.
5. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77:504-514.
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
7. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
8. McKenna WJ, Chew CYC, Oakley CM. Myocardial infarction with normal coronary angiogram: Possible mechanism of smoking risk in coronary artery disease. Br Heart J. 1980;43:493-498.,
9. Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med. 1999;340:1221-1227.
10. Glynn RJ, Brock DB, Harris T, et al. Use of antihypertensive drugs and trends in blood pressure in the elderly. Arch Intern Med. 1995;155:1855-1860.
11. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population: Data from the Heath Examination Surveys, 1960-1991. Hypertension. 1995;26:60-69.
12. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of anti-hypertensive medication use among older adults, 1989-1992: An effect of major clinical trials on clinical practice? JAMA. 1995;273:1436-1438.
13. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
14. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
15. The ALLHAT Officers and Coordinator for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treament to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
16. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA. 2001;285:2719-2728,
17. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860
18. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet. 2000;356:1949-1954.
19. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
20. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: Design and rationale. Ann Epidemiol. 1991;1:263-276.
21. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358-366.
22. Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1995;5:270-277.
23. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: Method and initial results in the Cardiovascular Health Study. J Clin Epidemiol. 1992;45:683-692.
24. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality control in the Cardiovascular Health Study. Clin Chem 1995;41:264-270.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem. 1972;18:499-501.
26. Fagan TC, Conrad KA, Mar JH, Nelson L. Effects of meals on hemodynamics: Implications for antihypertensive drug studies. Clin Pharmacol Ther. 1986;39:255-260.
27. Kohara K, Uemura K, Takata Y, Okura T, Kitami Y, Hiwada K. Postprandial hypotension: Evaluation by ambulatory blood pressure monitoring. Am J Hypertens. 1998;11:1358-1363.
28. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health Study. Ann Epidemiol. 1995;5:278-285.
29. Price TR, Psaty B, O'Leary D, Burke G, Gardin J, for the Cardiovascular Health Study Research Group. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:504-507.
30. Furberg CD, Manolio TA, Psaty BM, et al. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Am J Cardiol. 1992;69:1329-1335.
31. Burt VL, Whelton P, Roccella E J, et al. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-311.
32. Pahor M, Guralnik JM, Salive ME, Chrischilles EA, Manto A, Wallace RB. Disability and severe gastrointestinal hemorrhage: A prospective study of community-dwelling older persons. J Am Geriatr Soc. 1994;42:816-825.
33. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
34. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
35. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. StatMed. 1997;16:2349-2380.
36. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians. Arch Intern Med. 2000;160:2281-2286.
37. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM . Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413-420.
38. Psaty BM, Furberg CD, Kuller LH, et al. The association between level of blood pressure and the risk of myocardial infarction, stroke and total mortality: The Cardiovascular Health Study. Arch Intern Med. 2001;161:1183-1192.
39. Kaplan RC, Psaty BM, Heckbert SR, Smith NL, Lemaitre RL. Blood pressure level and incidence of myocardial infarction among patients treated for hypertension. Am J Public Health. 1999;89:1414-1417.
40. Klungel OH, Kaplan RC, Smith NL, et al. Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. Stroke. 2000;31:420-424.
41. Vasan RS, Larson MG, Lejp EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet. 2001;358:1682-1686.
42. Vassan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-1010.
43. Kostis JB, Weber MA, Alderman MH, et al. OPERA: Design and rationale for a novel placebo-control trial testing the benefits of blood pressure reduction in patients with stage I isolated systolic hypertension [abstract]. Am J Hypertens. 2000;13(pt 2);70A.
44. Moser M. Is it time for a new approach to the initial treatment of hypertension? Arch Intern Med. 2001;161:1140-1144.
45. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
46. Psaty BM, Savage PJ, Tell GS, et al. Temporal patterns of antihypertensive medication use among elderly patients: The Cardiovascular Health Study. JAMA. 1993;270:1837-1841.
47. Monane M, Glynn RJ, Gurwitz JH, et al. Trends in medication choices for hypertension in the elderly: The decline of the thiazides. Hypertension. 1995;25:1045-1051.
48. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: Do the JNC recommendations affect prescribing? JAMA. 1997;278:1745-1748.
49. Siegel D, Lopez J, Meier J. Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996. Am J Hypertens. 1998;11:1271-1278.
50. Siegel D, Lopez J, Meier J, Cunningham F. Changes in the pharmacologic treatment of hypertension in the Department of Veterans Affairs 1997-1999: Decreased use of calcium antagonists and increased use of beta-blockers and thiazide diurectics. Am J Hypertens. 2001;14:957-962.
51. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American Colledge of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute MI). J Am Coll Cardiol. 1996;28:1328-1428.
52. North of England Stable Angina Guideline Development Group. North of England evidence-based guidelines development project: Summary version of evidence-based guideline for the primary care management of stable angina. BMJ. 1996;312:827-832.
53. Task Force on the Management of Stable Angina Pectoris. Management of stable angina pectoris: Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 1997;18:394-413.
54. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: Executive summary and recommendations. Circulation. 1999;99:2829-2848.
55. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations. Circulation. 1999;100:1016-1030.
56. Medical Research Council Working Party. Medical Research Council trial oftreatment of hypertension in older adults: Principal results. BM J. 1992;304:405-412.
57. Psaty BM, Smith NS, Siscovick DS, et al. Health outcomes associated with anti-hypertensive therapies used as first-line agents: A systematic review and meta-analysis. JAMA. 1997;277:739-745.
58. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
59. Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985-1996. Circulation. 1999;99:2055-2057.
60. Ray WA, Schaffner W, Oates JA. Therapeutic choice in the treatment of hypertension: Initial treatment of newly diagnosed hypertension and secular trends in the prescribing of antihypertensive medications for Medicaid patients. Am J Med. 1986;81(suppl 6c):9-16.
61. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.